

PRESS RELEASE

Collectis receives payment for license to homologous recombination patents

Paris, April 4, 2011 – Collectis (Alternext: ALCLS), the genome engineering specialist, has announced today that it has signed a license agreement with a pharmaceutical company covering certain uses of its homologous recombination technology patents and patent applications, in the oncology therapeutic field. This agreement has triggered an immediate payment of €3M (\$4.2M) to Collectis. Further details of the arrangement have not been disclosed.

About Collectis

Collectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, bioresearch and agriculture. Collectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris. More information at www.collectis.com



Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

For further information, please contact:

Collectis

Sylvie Delassus
Senior VP Corporate Communication
+ 33 (0)1 41 83 99 00
media@collectis.com